Information Provided By: 
Fly News Breaks for April 25, 2018
BIIB
Apr 25, 2018 | 07:48 EDT
As reported previously, Baird analyst Brian Skorney upgraded Biogen to Outperform from Neutral. The analyst believes the shares are "too cheap" and its MS business appears more stable than he had been concerned about. He also believes its Spinraza asset is underappreciated and the company is poised for M&A to work in its favor. Skorney reiterated his $323 price target on Biogen shares.
News For BIIB From the Last 2 Days
There are no results for your query BIIB
